WST-057
Phase 3- Indications
- Diabetic peripheral neuropathy
Company intelligence / Profile preview
WinSanTor focuses on developing treatments for peripheral neuropathies with no current effective therapies. They are advancing a drug candidate based on repurposing an active ingredient used internationally for decades. The company aims to accelerate approval processes globally with a patient-centered approach. Their research shows potential in reversing nerve damage associated with diabetic and other forms of peripheral neuropathies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on WinSanTor Inc..